静脉-动脉体外膜氧合治疗难治性心源性休克幸存者的长期功能与生活质量结局
这项单中心观察性研究纳入2016年2月至2021年12月间法国某学术医院ICU连续收治的静脉-动脉ECMO治疗后存活出院的成年患者,评估至少1年后的功能结局和生活质量。79例出院幸存者中65例在中位随访2.8年(1.2-4.2年)时完成评估,35例(54%)改良Rankin量表评分为0或1分(功能结局良好)。ICU入住特征、血清神经生物标志物(神经元特异性烯醇化酶、S100B)及ECMO期间脑电图结果与功能结局无关联;男性是功能结局良好的唯一相关因素(校正OR 4.19,95%CI 1.35-14.5)。15%患者报告中度至重度生活质量问题,功能结局良好者在EQ-5D-5L各维度和SF-36躯体及心理评分均更优。作者认为需针对性长期随访和支持。
要点
- 79例静脉-动脉ECMO存活出院患者中65例完成中位2.8年随访,35例(54%)改良Rankin量表评分为0或1分,功能结局良好。
- 15%患者报告中度至重度生活质量问题,主要涉及活动能力、疼痛/不适和心理健康。
- 男性是功能结局良好的唯一相关因素(校正OR 4.19,95%CI 1.35-14.5)。
- ICU入住特征、血清神经元特异性烯醇化酶和S100B、ECMO期间脑电图结果与功能结局无关联。
- 功能结局良好者在EQ-5D-5L所有维度和SF-36躯体及心理评分均优于功能结局不良者。
适用人群与场景
- 法国某学术医院ICU 2016年2月至2021年12月连续收治的静脉-动脉ECMO治疗后存活出院的成年患者。
诊断标准与关键阈值
- 功能结局良好定义为改良Rankin量表评分0或1分,即无影响日常活动的功能受限。
研究设计与关键结果
- 单中心观察性研究,79例静脉-动脉ECMO存活出院患者中65例在中位随访2.8年(1.2-4.2年)时完成评估。
- 主要终点:35/65例(54%)改良Rankin量表评分为0或1分,功能结局良好。
- 次要终点:15%患者报告中度至重度生活质量问题,主要涉及活动能力、疼痛/不适和心理健康。
- 男性是功能结局良好的唯一相关因素(校正OR 4.19,95%CI 1.35-14.5)。
- ICU入住特征、血清神经生物标志物(神经元特异性烯醇化酶、S100B)及ECMO期间脑电图结果与功能结局无关联。
- 功能结局良好者在EQ-5D-5L所有维度和SF-36躯体及心理评分均更优。
证据类型、等级与局限
- 证据类型:单中心观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,约半数静脉-动脉ECMO幸存者获得良好的长期功能结局,但部分患者存在持续的功能受限,尤其涉及躯体功能和心理健康,需针对性长期随访和支持。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Long-term functional outcomes and health-related quality of life (HRQoL) in survivors of cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation (ECMO) remain poorly understood.
OBJECTIVES: This study aimed to evaluate these outcomes in a cohort of venoarterial ECMO survivors.
DESIGN, SETTING, AND PARTICIPANTS: This single-center observational study was conducted in the ICU of a French academic hospital and included consecutive adult patients treated with venoarterial ECMO who were discharged alive between February 2016 and December 2021.
MAIN OUTCOMES AND MEASURES: The primary endpoint was a favorable functional outcome at least one year after ICU discharge, defined as a score on the modified Rankin Scale of 0 or 1, indicating no functional limitations affecting usual activities. Secondary endpoints included HRQoL, assessed using the EuroQol 5D five levels (EQ-5D-5L) and 36-item short-form health survey (SF-36) questionnaires. Of 79 hospital survivors, 65 patients were evaluated after a median follow-up of 2.8 years (1.2-4.2 yr). A favorable functional outcome was observed in 35 of 65 patients (54%). No association was found between ICU admission characteristics, serum neurobiomarkers (neuron-specific enolase, S100B), electroencephalogram findings during venoarterial ECMO, and functional outcome. Male sex was the only parameter associated with higher odds of favorable functional outcome (adjusted odds ratio, 4.19; 95% CI, 1.35-14.5). HRQoL assessments showed moderate-to-severe issues in 15% of patients, mainly affecting mobility, pain/discomfort, and mental health. Patients with favorable outcomes reported better scores across all domains of the EQ-5D-5L and higher scores on both the physical and mental components of the SF-36.
CONCLUSIONS AND RELEVANCE: Approximately half of venoarterial ECMO survivors achieved excellent long-term functional outcomes. Nonetheless, a subset experienced ongoing limitations, particularly related to physical function and mental health, underscoring the need for targeted long-term follow-up and support.
参考来源
- Ortuno S, Bachelet D, Varnet O, et al. Long-Term Functional and Quality-of-Life Outcomes in Survivors of Refractory Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation. Crit Care Explor. 2025. PMID: 41329803. doi:10.1097/CCE.0000000000001359
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。